Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN
09445-cover-momson.jpg

November 14, 2016 Cover

Volume 94, Issue 45

After a controversial drug approval, biotech firms and patient advocacy groups look for a consensus on the design of trials for future drugs

Cover image:

Credit:

Full Article
Volume 94 | Issue 45

All Issues

Business

After eteplirsen: Duchenne stakeholders contemplate what comes next

After a controversial drug approval, biotech firms and patient advocacy groups look for a consensus on the design of trials for future drugs

  • How do chemists’ salaries stack up?

    ACS’s annual employment survey shows unemployment down and salaries steady in 2016

  • Periodic graphics: Why Li-ion batteries catch fire

    Chemical educator and Compound Interest blogger Andy Brunning reveals reasons why the compact components sometimes burst into flame

  • Gene therapy is ready for its comeback

    Clinical successes, focused start-ups, and pharma’s attention push genetic remedies closer to market

ADVERTISEMENT
image name

Periodic graphics: Why Li-ion batteries catch fire

Chemical educator and Compound Interest blogger Andy Brunning reveals reasons why the compact components sometimes burst into flame

ADVERTISEMENT
ADVERTISEMENT